Thu Sep 26 14:00:00 UTC 2024: ## PPARγ Agonist Shows Promise in Treating Kidney Stones by Regulating Mitochondrial Dynamics
**Changsha, China** – A new study published in PLOS ONE highlights the potential of PPARγ agonists in treating calcium oxalate nephrolithiasis, the most common type of kidney stone. Researchers from Central South University discovered that calcium oxalate crystals induce mitochondrial fission, leading to increased oxidative stress and apoptosis in renal tubular epithelial cells (TECs), ultimately contributing to kidney damage.
The study, conducted on both rats and human proximal tubular cells (HK2), found that PPARγ agonists, specifically troglitazone, effectively alleviated mitochondrial fission and apoptosis in TECs, leading to improved renal function and reduced oxidative stress, inflammation, and fibrosis.
“Our findings suggest that increased mitochondrial fission in renal tubular epithelial cells is a critical component of kidney injury caused by calcium oxalate stones,” said lead author Junfa Liu. “Regulating mitochondrial dynamics represents a promising approach for calcium oxalate nephrolithiasis.”
The researchers found that PPARγ agonists promote mitochondrial biogenesis and inhibit mitochondrial fission by upregulating PGC1-α, a key regulator of mitochondrial function. This mechanism ultimately reduces oxidative stress and inflammation, protecting TECs from damage and improving overall renal function.
The study provides compelling evidence for the potential therapeutic benefits of PPARγ agonists in treating kidney stones. Further research is needed to explore the long-term effects and clinical applications of these agonists in humans.
“These findings open new avenues for exploring innovative therapeutic strategies for calcium oxalate nephrolithiasis, potentially leading to improved treatment outcomes for patients with this common disease,” said Dr. Zhitao Dong, senior author of the study.
First Piper 